Pharmaceutical Business review

Mylan revenues up 12% in Q1

The company has reported net earnings of $104.55m, compared to $94.27m for the same period prior year.

For the first quarter of 2011, Mylan‘s earnings from operations was $211.68m, as compared to $198.51m for the same period last year.

Gross profit for the quarter ended 31 March 2011 was $590.9m, compared to $516.3m for the same period in 2010.

Mylan chairman and CEO Robert Coury said they are reaffirming their 2011 adjusted diluted EPS guidance of $1.90 to $2.10 per share, and their 2013 growth targets.